Poolbeg Pharma, an infectious disease firm spun out from Irish vaccine research company Open Orphan, has been granted a patent by the US Patent and Trademark Office (USPTO). The US
Poolbeg Pharma has been granted a patent in the United States for the treatment of hypercytokinaemia using its new influenza drug POLB 001. The US patent covers the use of
Poolbeg Pharma has released new data from a human challenge trial that shows its treatment has strong potential in dampening inflammation in blood and tissues in influenza and other viral
Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a leading infectious disease focused biopharmaceutical company, has announced that further to its announcement on 4 October 2022, it has been granted a patent by the US Patent and
Poolbeg Pharma – a company focused on developing infectious disease therapies – has announced data from its bacterial lipopolysaccharide (LPS) human challenge trial for POLB 001. The treatment is a
Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF’), a leading infectious disease focused biopharmaceutical company, has announced the data readout from the bacterial lipopolysaccharide (‘LPS’) human challenge trial for POLB 001, a viral
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost
In the time that has passed since SLAS2022 in Boston, USA, the drug discovery industry has had to deal with all manner of external obstacles, from the war in Ukraine,
Here’s an investment idea that starts with large blue-chip companies, but has significant trickle-down potential to at least three smaller, growth companies listed in the UK. Chances are RSV, or
Poolbeg Pharma (LON:POLB / OTCQB:POLBF) Investment Case with CEO Jeremy Skillington. Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company with a unique capital light model. The company is focus on
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
